Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesImpact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitisA Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel DiseasesThe burden of inflammatory bowel disease in EuropeTherapeutic challenges of managing inflammatory bowel disease in the elderly patient.Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationAdoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelRandomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease.A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.New strategies for treatment of inflammatory bowel diseaseFecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation.In-silico analysis of inflammatory bowel disease (IBD) GWAS loci to novel connections.IBD and the gut microbiota--from bench to personalized medicine.The Emerging Adult with Inflammatory Bowel Disease: Challenges and Recommendations for the Adult GastroenterologistOut-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds.Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-UpCosts of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in PolandCost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximabCost-effectiveness of Crohn's disease post-operative careDemographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.Molecular patterns in human ulcerative colitis and correlation with response to infliximabUsefulness of sulfasalazine for patients with refractory-ulcerative colits.Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in miceIs early limited surgery associated with a more benign disease course in Crohn's disease?Trends and Factors Affecting Hospitalization Costs in Patients with Inflammatory Bowel Disease: A Two-Center Study over the Past Decade.Comparative effectiveness of infliximab and adalimumab for Crohn's disease.Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics.Inflammatory bowel disease course in Crohn's disease: is the natural history changing?Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.Impact of inflammatory bowel disease on disability.Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.The epidemiology of inflammatory bowel disease.Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.Biologic agents for IBD: practical insights.Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.
P2860
Q24185835-880659B1-C538-4B18-B275-067B17D61967Q26771136-F9450BD4-7F8F-4F24-B369-3E00344C803DQ26775384-0EA4211E-1FE9-44E2-BF1D-88C85458F3D8Q28285200-D5021C44-196C-49DC-826A-2768C547DAAEQ30251570-F8D983E3-914F-4463-9384-A65C2BB91D43Q33646458-6BD6442F-295A-4931-AC5E-EFAEA1ECAA69Q33667897-58217585-F53A-4736-A64E-CB8B86B00082Q33740641-66977823-A64A-49CB-AEB0-660113108CA4Q34067969-880E7799-385A-4A0B-A905-239C2748CBECQ34353032-1327EB0B-D188-4A18-BF3E-90C5BF3B4B44Q35069447-906456D8-D285-46DA-B7B9-4AC0415BB27AQ35069777-A029726E-CEC9-4386-9548-5B04EB8E57CAQ35114682-98D08F95-02B0-4AE0-BFFE-7FAD6D2D7D73Q35191804-7D24B701-F841-480D-A40C-980267725809Q35575495-6ED4AD77-58DE-4D7C-83D7-FDE8564C081EQ35614324-AD300D15-7C80-4DBD-879D-FAE3EAA2592FQ35624933-EB2C1D54-47D1-4D75-8D7B-3C14829B8BA9Q35897490-84D979BA-862A-4911-B9D0-3D470C26D50CQ35995603-F9E86A41-4C17-46D7-9056-4AA5F7E5901EQ36192570-926FC150-03B0-4916-9808-06874609CC71Q36228380-502D259F-CF6D-4698-94C3-825B1766BAA5Q36714704-0E42BBE7-87CB-4F2C-8EC6-5D89C43A122EQ36747868-84190E06-8E98-48C5-AA59-D30F9C177F02Q36905970-2450F07B-4DA3-4E3F-92BE-273609218E7AQ37098416-5DF0CDE3-3DD1-4D4C-82D5-14F284167BC5Q37175815-4EF2A685-E1FB-46A6-BDA3-598736D678C8Q37236388-7D238640-2425-45C8-AF18-AA53D293B9EBQ37237823-C4DE3F25-82A7-4939-B043-3995DDD39F3AQ37334129-C0A81290-D9F9-4FFA-A171-B7C93DE068A3Q37338282-1037400D-A9A4-490D-B3BB-90104E5885ACQ37445629-52F77D5E-C3C9-4839-87AB-F05E0AC9E7FAQ37572837-7F4FE21D-6418-4B47-A776-B00F010529F4Q37660681-5F31C086-1381-4BF9-873B-9DFE07F99E73Q38248218-6731A18B-DB4E-452F-8454-C38B55DF5CB7Q38251199-4C540D44-6F83-4EDF-89AF-F40F5E017467Q38345847-3324E335-13D3-4F75-BAB7-A945C5D4EB64Q38357796-D3B1ED1E-3A77-4834-8B78-B8AACC8DBC8FQ38488635-8BF28C19-264C-4632-919E-F97ACFD70A1AQ38568898-C2089BDA-ABAE-4B93-A9AA-3D03CC43BC0BQ38608975-711A989D-C601-4B07-AE54-835DDEBB207E
P2860
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Healthcare costs of inflammato ...... : results from the COIN study.
@en
Healthcare costs of inflammato ...... : results from the COIN study.
@nl
type
label
Healthcare costs of inflammato ...... : results from the COIN study.
@en
Healthcare costs of inflammato ...... : results from the COIN study.
@nl
prefLabel
Healthcare costs of inflammato ...... : results from the COIN study.
@en
Healthcare costs of inflammato ...... : results from the COIN study.
@nl
P2093
P2860
P1433
P1476
Healthcare costs of inflammato ...... : results from the COIN study.
@en
P2093
Ad A van Bodegraven
Andrea E van der Meulen-de Jong
Bas Oldenburg
C Janneke van der Woude
COIN study group and the Dutch Initiative on Crohn and Colitis
Cees H M Clemens
Clemens J M Bolwerk
Cyriel Y Ponsioen
Dirk J de Jong
Gerard Dijkstra
P2860
P356
10.1136/GUTJNL-2012-303376
P407
P577
2012-11-07T00:00:00Z